Patent intelligence · US
US 9574243
Compositions and methods for the treatment of influenza infection
Compositions and methods for the treatment of influenza infection
Patent details — US 9574243
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 21, 2017
- Expiration
- Feb 16, 2037
- Applicant
- Lakewood Amedex, Inc.
- Claims
- 18
- CPC classes
- A61K, A61K38/00, A61K39/145, A61P
Quick answer
US 9574243 (Compositions and methods for the treatment of influenza infection) is held by Lakewood Amedex, Inc.. Status: granted. Granted Feb 21, 2017. Expires Feb 16, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Lakewood Amedex, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K38/00, A61K39/145, A61P, A61P31/16
More from Lakewood Amedex, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12156883
Bisphosphocin gel formulations and uses thereof
granted -
US 12054509
Antimicrobial compounds, compositions, and uses thereof
granted -
US 12030908
Antimicrobial compounds, compositions, and uses thereof
granted -
US 11795192
Antimicrobial compounds, compositions, and uses thereof
granted -
US 11377468
Antimicrobial compounds, compositions, and uses thereof
granted -
US 11123357
Methods and compositions for treating oral mucositis
granted -
US 11096954
Bisphosphocin gel formulations and uses thereof
granted -
US 10981943
Antimicrobial compounds, compositions, and uses thereof
granted
Frequently asked questions
What is US patent 9574243?
US 9574243 (Compositions and methods for the treatment of influenza infection) is held by Lakewood Amedex, Inc.. Status: granted. Granted Feb 21, 2017. Expires Feb 16, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9574243?
Lakewood Amedex, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 18 pharmaceutical patents for this assignee.
When does US 9574243 expire?
Our index shows an expiration date of Feb 16, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.